CRWD -31.57AMD -14.48AVGO -59.47TVE.TO 0.45BHP -2.54BBD.B.TO -0.79OWL 0.695
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.72
+0.38 (1.48%)
as of Jun 4, 2026, 7:03:20 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Feb 24, 2022
(A Top Pick Sep 24/20, Up 28.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has triggered its stop at $46. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 23%, when combined with the previous recommendation to cover half.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$45.59

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 24, 2022
Suffered recently a bit, as shine from Covid has worn off. Great defensive growth name. Likes healthcare in general. Don't sell it to buy LLY, but nothing against LLY. Trades at 6x forward earnings. Great cardio drug that could be a gamechanger, strong pipeline. Yield is 3.5%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$45.59

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 18, 2022
Has recently sold shares in company. Long term, pandemics will remain a fact of life. Has good pipeline of new drugs being developed.
Photo of Jamie Murray Jamie Murray
No
Unlock Rating
$48.53

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 03, 2022
R&D has become much more concentrated. Cashflow windfall being used to expand pipeline. CEO has done exceptional job navigating the vaccine environment. Tuck-in acquisitions. Executing well, deserves the multiple bump. Yield is 3%. (Analysts’ price target is $58.53)
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$53.30

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Jan 20, 2022
(A Top Pick Sep 24/20, Up 51.5%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend tailing up the stop (from $42) to $46.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$54.05

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 12, 2022
One of the world's largest biopharma companies. Expected revenue of 97B USD this year. Likes it because of its rapidly improving pipeline, especially the cardio drug. Vaccine will produce cashflow windfalls over the near term, plus lots of runway. Continuing shots needed, anti-viral pill will be in high demand. Good valuation. Yield is 2.86%, expected to grow. (Analysts’ price target is $56.61)
Photo of Stan WongStan Wong
Owned
Unlock Rating
$56.59

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 06, 2022
Leadership position in vaccine fight. If you invest here, and pandemic goes away, PFE's fortunes could regress to the mean. It won't have the wind at its back anymore. The uncertainty makes him pass.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$55.34

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 08, 2021
He stays away from drug companies, always forced to do acquisitions. Costly and competitive business. Pressures from government. Boost from pandemic, and this will continue. Reasonable valuation. He prefers medical devices, where you don't need a PhD to understand what's coming next. Attractive yield about 3%.
Photo of John O'Connell, CFAJohn O'Connell, CFA
No
Unlock Rating
$51.31

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 03, 2021
Among the vaccine stocks, he feels safe with this. They're coming out with their Covid pill treatment.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$54.27

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 22, 2021
Don't sell. Incredibly low valuation. Well positioned, well diversified. Established distribution network. Great long-term growth story over time.
Photo of John ZechnerJohn ZechnerUnlock Rating
$51.34

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Oct 29, 2021
They face a patent cliff in 2022, so will the Covid booster cover this? They report Tuesday.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$43.74

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 28, 2021
Has tended to peak out at 4x book value, around $50. Vaccine potential has petered out. FMV potential is 55% higher than current price. More likely to have a further setback, with $37-38 as his downside target. The stock's already given at the office and it's not prepared to give at home.
Photo of Ross HealyRoss HealyUnlock Rating
$43.14

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 18, 2021
All healthcare stocks have been pressured. PFE is protected by their near-4% dividend. We will all need their Covid booster shot.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$41.32

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Oct 04, 2021
The performance has been disappointing. The problem with big, old pharma is that it is not enough to move the needle. He thinks it is a good one to put away. They are a little constrained on the new product side. He'd suggest an ETF of biotech companies.
Photo of John ZechnerJohn ZechnerUnlock Rating
$42.42

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 30, 2021
Great dividend yield, not trading at a high multiple. Not a pure play. Covid vaccine issue will continue for years to come. Likes healthcare, but it tends to come up as a US political issue. A great story here. He owns JNJ instead.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$43.44

Stock price when the opinion was issued

$25.72

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 151 to 165 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PANW -3.74$276.69
GS 51.85$1092.87
AAPL 1.59$311.85
BUG -0.365$36.405
ABBV 6.495$223.625

Today's Top Picks

CRWD -31.57$716.04
AMD -14.48$528.04
AVGO -59.47$419.76
TVE.TO 0.45$14.02
BHP -2.54$88.31

Popular Articles

Latest Sell Signals

AVGO -59.47$419.76
LDOS 1.85$126.2
CME 0$
ULTA -8.555$462.655
MRVL 11.85$313.5

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bryn Talkington

Bryn Talkington

Requisite Capital Management

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica